A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting. J. Can. Res. Updates [Internet]. 2023 Dec. 11 [cited 2025 Oct. 22];12:49-53. Available from: https://www.neoplasiaresearch.com/index.php/jcru/article/view/739